Cytogen Corporation - SWOT Analysis

Cytogen Corporation - SWOT Analysis
  • Report price : $ 125
  • Publication date : April 2008
  • Length : 24 pages

Get this Report Now !

Cytogen Corporation - SWOT Analysis

Datamonitor's Cytogen Corporation - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.

Cytogen is a specialty pharmaceutical company focused on building, developing, and commercializing a portfolio of oncology products for the treatment and care of cancer patients. The company currently markets Quadramet (samarium Sm-153 lexidronam injection), Prostascint (capromab pendetide), and Soltamox (tamoxifen citrate) to the US oncology market. Cytogen is headquartered in Princeton, New Jersey and employed 95 people as of December 2006. The company recorded revenues of $17 million during the fiscal year ended December 2006, an increase of 8.8% over 2005. The operating loss of the company was $30 million during fiscal year 2006, as compared to $29 million in 2005. The net loss in fiscal year 2006 was $29 million, as compared to $28 million in 2005.

Scope of the Report

- Provides all the crucial company information required for business and competitor intelligence needs
- Contains a study of the major internal and external factors affecting the company in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement

Reasons to Purchase

- Support sales activities by understanding your customers’ businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors’ business structure, strategy and prospects
- Obtain the most up to date company information available

RELATED REPORTS

Impact of Pharmacogenomics on Public Healthcare Policy: Educating patients, payors and healthcare providers

Impact of Pharmacogenomics on Public Healthcare Policy: Educating patients, payors and healthcare providers

  • $ 3 835
  • March 2008
  • 171 pages

Impact of Pharmacogenomics on Public Healthcare PolicyImmense advances in genetic code decipherment over the last decade have recently led to personalized medicine, or ‘the right drug for the right person’, becoming an achievable concept. Pharmacogenomics (PGx) embodies the principles of persona ...

Industries : Pharmaceutical | Countries : USA, Japan

Stakeholder Opinions: Bone Metastases - Impending patent expiries may help make or break newer agents

Stakeholder Opinions: Bone Metastases - Impending patent expiries may help make or break newer agents

  • $ 3 800
  • March 2008
  • 100 pages

IntroductionBone metastases are a complication of some advanced cancers including cancers of the breast, lung, prostate, kidney and thyroid. The incidence of bone metastases across these tumor types in the seven major markets is forecasted to total 225,174 in 2008. While treatment with bisphosphonat ...

Industries : Pharmaceutical | Countries : USA

The Pharmaceutical Industry 2008: Current and Future Trends and Strategic Issues Shaping Pharma

The Pharmaceutical Industry 2008: Current and Future Trends and Strategic Issues Shaping Pharma

  • $ 5 700
  • March 2008
  • 187 pages

IntroductionToday, pharma companies face growing competition from generics and me-too drugs, combined with increasingly tough P&R, a clamp down on healthcare spending, and the need to treat patients for longer due to the aging population. These factors threaten both current and future revenues promp ...

Industries : Pharmaceutical | Countries : USA, China, Japan, India, Spain, France, United Kingdom

Stakeholder Opinions: Systemic Lupus Erythematosus - Market set to enter era of biologic therapies

Stakeholder Opinions: Systemic Lupus Erythematosus - Market set to enter era of biologic therapies

  • $ 3 800
  • March 2008
  • 108 pages

IntroductionSLE is a chronic, life-long and potentially fatal autoimmune disease characterized by multiple system distress and unpredictable flares. Therapy is largely off-label and a huge demand exists for new SLE therapies because of the potential for serious side effects from drugs currently used ...

Industries : Pharmaceutical | Countries : Mexico, Canada, USA, China, Japan, India, Croatia, Germany, Spain, France, Italy, United Kingdom

Pharmaceutical Supply chain strategies: Reassessing product distribution to cut costs and improve supply chain management

Pharmaceutical Supply chain strategies: Reassessing product distribution to cut costs and improve supply chain management

  • $ 3 800
  • March 2008
  • 64 pages

IntroductionIdeally drug supply should be a simple and transparent chain that connects the manufacturer and patient in as few steps as possible, however in practice it can be a highly circuitous one that includes several intermediaries before reaching a pharmacy. This increases the risk of counterfe ...

Industries : Pharmaceutical | Countries : USA, United Kingdom

Merck & Co., Inc. - SWOT Analysis

Merck & Co., Inc. - SWOT Analysis

  • $ 125
  • April 2008
  • 40 pages

Datamonitor's Merck & Co., Inc. - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy. M ...

Industries : Pharmaceutical | Countries : USA

Shire plc - SWOT Analysis

Shire plc - SWOT Analysis

  • $ 125
  • April 2008
  • 26 pages

Datamonitor's Shire plc - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy. Shire Pha ...

Industries : Pharmaceutical | Countries : USA, United Kingdom

Endo Pharmaceuticals Holdings Inc. - SWOT Analysis

Endo Pharmaceuticals Holdings Inc. - SWOT Analysis

  • $ 125
  • April 2008
  • 26 pages

Datamonitor's Endo Pharmaceuticals Holdings Inc. - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue line ...

Industries : Pharmaceutical | Countries : USA

Cardinal Health, Inc. - SWOT Analysis

Cardinal Health, Inc. - SWOT Analysis

  • $ 125
  • April 2008
  • 39 pages

Datamonitor's Cardinal Health, Inc. - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strateg ...

Industries : Pharmaceutical | Countries : USA

ISTA Pharmaceuticals, Inc. - SWOT Analysis

ISTA Pharmaceuticals, Inc. - SWOT Analysis

  • $ 125
  • April 2008
  • 24 pages

Datamonitor's ISTA Pharmaceuticals, Inc. - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and st ...

Industries : Pharmaceutical | Countries : USA

reportlinker.com © Copyright 2009. All rights reserved

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.